SCHEMBL2631387

SCHEMBL2631387

CC(C)(CCCCCCCCCCCO)[Si](O)(c1ccccc1)c1ccccc1

nearest known ligand 0.33

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNH3 Q9ULD8 1/20 0.33
CNR2 P34972 3/20 0.33
CNR1 P21554 1/20 0.33
SIGMAR1 Q99720 1/20 0.32
TBXAS1 P24557 1/20 0.31
CYP4F2 P78329 1/20 0.31
CYP4A11 Q02928 1/20 0.31
MPO P05164 1/20 0.31
ESR2 Q92731 1/20 0.31
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30
LTB4R Q15722 1/20 0.30
MAPK1 P28482 1/20 0.30
PDE5A O76074 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8470193 1.00 KCNH3 (0.33) KCNH3CNR2CNR1SIGMAR1TBXAS1
SCHEMBL8456254 1.00 KCNH3 (0.33) KCNH3CNR2CNR1SIGMAR1TBXAS1
SCHEMBL15686642 1.00 KCNH3 (0.33) KCNH3CNR2CNR1SIGMAR1TBXAS1
SCHEMBL15686638 1.00 KCNH3 (0.33) KCNH3CNR2CNR1SIGMAR1TBXAS1
SCHEMBL15686603 1.00 KCNH3 (0.33) KCNH3CNR2CNR1SIGMAR1TBXAS1
SCHEMBL15686651 1.00 KCNH3 (0.33) KCNH3CNR2CNR1SIGMAR1TBXAS1
SCHEMBL8482393 0.98 SIGMAR1 (0.33) KCNH3CNR2CNR1SIGMAR1ESR2
SCHEMBL8454747 0.96 ESR2 (0.32) KCNH3SIGMAR1ESR2NR1H2NR1H3
SCHEMBL13192982 0.91 KDM4E (0.37)
SCHEMBL13192948 0.91 ACLY (0.38) CNR2CNR1TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170145499-A1 METHODS FOR INDEXING SAMPLES AND SEQUENCING MULTIPLE POLYNUCLEOTIDE TEMPLATES ILLUMINA CAMBRIDGE LIMITED (US) 2017-05-25 US disclosed
US-20170021325-A1 Preparation of Templates for Nucleic Acid Sequencing SOLEXA LIMITED (GB) 2017-01-26 US disclosed
US-9512478-B2 Methods for indexing samples and sequencing multiple polynucleotide templates ILLUMINA CAMBRIDGE LIMITED (GB) 2016-12-06 US disclosed
US-9498763-B2 Preparation of templates for nucleic acid sequencing ILLUMINA CAMBRIDGE LIMITED (GB) 2016-11-22 US disclosed
US-9422318-B2 Epoxyeicosatrienoic acid analogs and methods of making and using the same THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2016-08-23 US disclosed
US-20160090623-A1 METHOD FOR PAIRWISE SEQUENCING OF TARGET POLYNUCLEOTIDES ILLUMINA CAMBRIDGE LIMITED (GB) 2016-03-31 US disclosed
US-9267173-B2 Method for pairwise sequencing of target polynucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2016-02-23 US disclosed
US-20150343410-A1 Preparation of Templates for Nucleic Acid Sequencing ILLUMINA CAMBRIDGE LIMITED (GB) 2015-12-03 US disclosed
US-20150336916-A1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-26 US disclosed
US-9127027-B2 Epoxyeicosatrienoic acid analogs and methods of making and using the same THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2015-09-08 US disclosed
US-8236505-B2 Method for pairwise sequencing of target polynucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2012-08-07 US disclosed
US-8182989-B2 Methods for indexing samples and sequencing multiple polynucleotide templates ILLUMINA CAMBRIDGE LTD. (GB) 2012-05-22 US disclosed
US-20120094848-A1 Method for pairwise sequencing of target polynucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2012-04-19 US disclosed
US-20120015823-A1 Methods for indexing samples and sequencing multiple polynucleotide templates ILLUMINA CAMBRIDGE LIMITED (GB) 2012-01-19 US disclosed
US-7960120-B2 Method for pair-wise sequencing a plurality of double stranded target polynucleotides ILLUMINA CAMBRIDGE LTD. (GB) 2011-06-14 US disclosed
EP-2298930-A1 Preparation of templates for nucleic acid sequencing Illumina Cambridge Limited (GB) 2011-03-23 EP disclosed
US-20110014657-A1 Method for sequencing a polynucleotide template ILLUMINA CAMBRIDGE LTD. 2011-01-20 US disclosed
US-7754429-B2 Method for pair-wise sequencing a plurity of target polynucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2010-07-13 US disclosed
US-20090118128-A1 Preparation of templates for nucleic acid sequencing ILLUMINA CAMBRIDGE LIMITED (GB) 2009-05-07 US disclosed
US-20090088327-A1 Method for sequencing a polynucleotide template SOLEXA LIMITED (GB) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336916-A1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME PTGER1, PTGES, PTGER2 KCNH3 4426/4885CNR2 390/4885CNR1 546/4885
US-20090118128-A1 Preparation of templates for nucleic acid sequencing RNGTT, POLRMT, POLM KCNH3 4305/4885CNR2 4573/4885CNR1 4500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.